Scott T. Reents
Known title: EVP, CHIEF FINANCIAL OFFICERCIK: 0001937048
Associated companies
Transaction History
| ABBV | ▼ Sell | Tax Withholding | 21,638 | $5.0M | 2/27/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 25,062 | $0 | 2/18/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 8,910 | $0 | 2/18/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 7,606 | $0 | 2/18/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 7,260 | $0 | 2/18/2026 | View on chart |
| ABBV | ▼ Sell | Open Market | 17,644 | $3.7M | 3/14/2025 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 10,973 | $2.2M | 2/28/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 5,845 | $0 | 2/13/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 2,398 | $0 | 2/13/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 7,608 | $0 | 2/13/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 8,912 | $0 | 2/13/2025 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 11,634 | $2.1M | 2/28/2024 | View on chart |
| ABBV | ▲ Buy | Option Exercise | 14,140 | $868K | 2/23/2024 | View on chart |
| ABBV | ▼ Sell | Open Market | 14,140 | $2.5M | 2/23/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 11,800 | $0 | 2/15/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 8,912 | $0 | 2/15/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 3,146 | $0 | 2/15/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 2,398 | $0 | 2/15/2024 | View on chart |
| ABBV | ▼ Sell | Open Market | 15,092 | $2.3M | 3/1/2023 | View on chart |
| ABBV | ▼ Sell | Open Market | 850 | $130K | 3/1/2023 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 12,683 | $2.0M | 2/28/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 3,146 | $0 | 2/16/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 18,715 | $0 | 2/16/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 4,366 | $0 | 2/16/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 2,398 | $0 | 2/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AbbVie Gains from Oncology Trial News and Dividend Appeal
AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.
AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.